Godwin, Colin D.
Laszlo, George S.
Fiorenza, Salvatore
Garling, Eliotte E.
Phi, Tinh-Doan
Bates, Olivia M.
Correnti, Colin E.
Hoffstrom, Benjamin G.
Lunn, Margaret C. http://orcid.org/0000-0003-0527-5575
Humbert, Olivier
Kiem, Hans-Peter http://orcid.org/0000-0001-5949-4947
Turtle, Cameron J.
Walter, Roland B. http://orcid.org/0000-0002-9268-3341
Article History
Received: 11 May 2020
Revised: 11 January 2021
Accepted: 26 January 2021
First Online: 15 February 2021
Compliance with ethical standards
:
: CDG received research funding from Immunogen and Pfizer. HPK is a consultant to and has ownership interests with Rocket Pharma and Homology Medicines and is a consultant to CSL Behring and Magenta Therapeutics. CJT received research funding from AstraZeneca, Juno Therapeutics/Bristol Myers Squibb, Minerva, Nektar Therapeutics, and TCR<sup>2</sup> Therapeutics; has ownership interests with ArsenalBio, Caribou Biosciences, Eureka Therapeutics, Myeloid Therapeutics, Precision Biosciences; is an inventor on a patent licensed to Juno Therapeutics; and is (or has been) a consultant to Amgen, ArsenalBio, Astra Zeneca, Caribou Biosciences, Century Therapeutics, Eureka Therapeutics, Myeloid Therapeutics, Nektar Therapeutics, PACT Pharma, Precision Biosciences, and T-CURX. RBW received laboratory research grants and/or clinical trial support from Amgen, Aptevo, Celgene, Immunogen, Macrogenics, Jazz, Pfizer, and Selvita; has ownership interests with Amphivena; and is (or has been) a consultant to Agios, Amphivena, Aptevo, Astellas, Bristol Myers Squibb, Celgene, Genentech, Janssen, Kite, Macrogenics, and Pfizer. The other authors declare no competing financial interests.